In August 2022, the FDA granted accelerated approval of T-DXd for the treatment of unresectable/metastatic NSCLC patients with an HER2 mutation, based on results of the DESTINY-Lung01 and DESTINY-Lung02 trials. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.